Product Information
QUETIAPINE ER 300 MG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.2717 per EA under NDC 00904680461. Its NADAC has been published 377 times since Jul 17, 2019.
FDA first approved this application on May 17, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904680461
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
QUETIAPINE FUMARATEApproval Type
Generic (ANDA)
FDA Application
ANDA204203FDA Approved
5/17/2017
TE Code
AB
On Market Since
8/22/2017
Pharmacological Classes
Price Statistics
The NADAC for QUETIAPINE ER 300 MG TABLET has been published 377 times since Jul 17, 2019, and over the history we have for it it has declined 57.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2717 per EA |
|---|---|
| All-time high | $0.6388 (Aug 14, 2019) |
| All-time low | $0.1954 (Nov 20, 2024) |
| 52-week high | $0.2805 |
| 52-week low | $0.2559 |
| Median price | $0.3306 |
| Average price | $0.3527 |
| Largest weekly change | +47.7% (Aug 21, 2024) |
| Weeks tracked | 377 |
| Tracking since | Jul 17, 2019 |
Generic Alternatives
The matcher finds 11 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 53% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Quetiapine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QUETIAPINE ER 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for QUETIAPINE ER 300 MG TABLET, manufactured by Major Pharmaceuticals, is $0.2717 per EA (NDC 00904680461), effective Sep 30, 2026.
How has the price of QUETIAPINE ER 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for QUETIAPINE ER 300 MG TABLET has declined 57.5%. It has been tracked across 377 weekly CMS publications since Jul 17, 2019.
What are the highest and lowest recorded NADAC prices for QUETIAPINE ER 300 MG TABLET?
Since Jul 17, 2019, the NADAC for QUETIAPINE ER 300 MG TABLET has ranged from a low of $0.1954 (Nov 20, 2024) to a high of $0.6388 (Aug 14, 2019), with a median of $0.3306 per EA.
Are there cheaper alternatives to QUETIAPINE ER 300 MG TABLET?
Yes. 11 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, QUETIAPINE FUMARATE 300 MG TAB, is $0.1275 per EA — about 53% below QUETIAPINE ER 300 MG TABLET.
Who manufactures QUETIAPINE ER 300 MG TABLET?
QUETIAPINE ER 300 MG TABLET (NDC 00904680461) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.